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Snakebite is a neglected tropical disease that causes 138,000 deaths each year. Neurotoxic 
snake venoms contain small neurotoxins, including three-finger toxins (3FTxs), which 
can cause rapid paralysis in snakebite victims by blocking postsynaptic transmission via 
nicotinic acetylcholine receptors (nAChRs). These toxins are typically weakly immunogenic 
and thus are often not effectively targeted by current polyclonal antivenom therapies. 
We investigated whether nAChR mimics, also known as acetylcholine binding proteins 
(AChBPs), could effectively capture 3FTxs and therefore be developed as a novel class 
of snake-generic therapeutics for combatting neurotoxic envenoming. First, we identified 
the binding specificities of 3FTx from various medically important elapid snake venoms 
to nAChR using two recombinant nAChR mimics: the AChBP from Lymnaea stagnalis 
and a humanized neuronal α7 version (α7-AChBP). We next characterized these AChBP-
bound and unbound fractions using SDS-PAGE and mass spectrometry. Interestingly, 
both mimics effectively captured long-chain 3FTxs from multiple snake species but 
largely failed to capture the highly related short-chain 3FTxs, suggesting a high level 
of binding specificity. We next investigated whether nAChR mimics could be used as 
snakebite therapeutics. We showed that while α7-AChBP alone did not protect against 
Naja haje (Egyptian cobra) venom lethality in vivo, it significantly prolonged survival times 
when coadministered with a nonprotective dose of antivenom. Thus, nAChR mimics are 
capable of neutralizing specific venom toxins and may be useful adjunct therapeutics 
for improving the safety and affordability of existing snakebite treatments by reducing 
therapeutic doses. Our findings justify exploring the future development of AChBPs as 
potential snakebite treatments.
Keywords: nicotinic acetylcholine receptors (nAChR), long-chain three-finger toxins (3FTx), acetylcholine binding 
proteins (AChBPs), snake venom neurotoxins, envenoming, therapeutics
nAChR Mimics as Snakebite TherapeuticsAlbulescu et al.
2 July 2019 | Volume 10 | Article 848Frontiers in Pharmacology | www.frontiersin.org
INTRODUCTION
Snakebite is a neglected tropical disease that results in high 
mortality (138,000 deaths per annum) and morbidity (~400,000 
cases per annum), and it is the rural impoverished people of 
the tropics who suffer the greatest burden (Gutiérrez et al., 
2017). Elapids (family Elapidae) are one of the main groups of 
medically important snakes responsible for severe envenoming 
and include the cobras (Naja spp.), kraits (Bungarus spp.), 
mambas (Dendroaspis spp.), and coral snakes (Micrurus spp.). 
Elapid envenoming often causes postsynaptic neurotoxic effects 
by blocking neuromuscular transmission that can culminate in 
respiratory paralysis and death (Gutiérrez et al., 2017). Three-
finger toxins (3FTxs) play a key role, with many competitively 
binding to postsynaptic neuromuscular and neuronal nicotinic 
acetylcholine receptors (nAChRs) to inhibit the binding of 
acetylcholine (Chang, 1979). Importantly, ever since the 
discovery of α-bungarotoxin, snake venom neurotoxins have 
been extensively employed for characterizing nAChRs and 
understanding the basis of neurotransmission. Therefore, a 
comprehensive knowledge of their targets and mechanisms of 
action remains important for a range of biological disciplines.
Three-finger toxins are one of many snake venom toxin 
types that are encoded by a multilocus gene family (Casewell 
et al., 2013). The frequent duplication of toxin-encoding genes 
coupled with bursts of accelerated evolution results in snake 
venom composition varying at every taxonomic level, including 
inter- and intraspecifically (Chippaux et al., 1991; Casewell et al., 
2013; Casewell et al., 2014). Moreover, elapid venom proteomes 
are usually dominated by 3FTxs, which typically consist of 
numerous isoforms that comprise over 60% of venom proteins 
(Tasoulis and Isbister, 2017). These are small disulfide-bond 
rich proteins with a globular core and three β-stranded loops 
that extend from the core as “fingers” and can be classified into 
short-chain, long-chain, weak and nonconventional neurotoxins, 
cardiotoxins, and others (Kessler et al., 2017). Short-chain 3FTxs 
are small proteins consisting of 60–62 amino acid residues that 
contain four disulfide bridges, while long-chain α-neurotoxins 
(long-chain 3FTxs) have 66–74 amino acid residues and display 
an additional disulfide bond.
The small size (~7–12 kDa) of these potent neurotoxins poses 
a therapeutic challenge—they are weakly immunogenic (Tan 
et al., 2016b; Wong et al., 2016), yet all snakebite therapeutics 
(antivenoms) are manufactured from IgG of venom-immunized 
animals. The antineurotoxic efficacy of current antivenoms is 
further compromised because only 10–15% of the resulting IgG 
binds venom proteins (Casewell et al., 2010), with the remainder 
generated in response to environmental antigens to which the 
animals are exposed. Furthermore, antivenom efficacy is highly 
snake species-specific, resulting in limited cross-reactivity to 
venom toxins not included in the immunizing mixture (Tan 
et al., 2016a; Oh et al., 2019)—an inevitable result of venom 
variation (Williams et al., 2011). To circumvent this challenge, 
many antivenom manufacturers use mixtures of venoms 
as immunogens. However, this often results in polyspecific 
antivenoms requiring much higher therapeutic doses [e.g., 5–10 
vials (50–100 ml) of ~50–100 mg/ml antibodies] to effect cure, 
which, in turn, results in high incidences of foreign protein-
related adverse reactions (de Silva et al., 2016) and prohibitively 
expensive treatment costs for impoverished snakebite victims 
[e.g., 48–315 USD/vial in Africa (Harrison et al., 2017)]. 
Therefore, a therapeutic approach providing cross-generic 
neutralization of snake venom neurotoxins (i.e., irrespective of 
the snake species responsible for the bite) and, at low therapeutic 
doses, would be highly valuable.
Acetylcholine binding proteins (AChBPs) are mimics of the 
extracellular ligand-binding domain of nAChRs and have been 
used extensively in structural studies of complexes of the receptor 
with a wide range of nicotinic agonists (Brejc et al., 2001), partial 
agonists (Hibbs et al., 2009), antagonists (Brams et al., 2011), 
and allosteric modulators (Spurny et al., 2015). AChBPs form 
pentameric complexes in which five subunits radially assemble 
around a central vestibule. The pharmacological properties of 
AChBPs from the freshwater snail Lymnaea stagnalis (Ls-AChBP) 
most closely resemble the human α7-nAChR (Smit et al., 2001), 
which is one of the most abundant nAChR subtypes in the 
brain. Other receptor mimics with different binding specificities 
have also been described, including a humanized version of the 
neuronal α7 receptor (α7-AChBP) (Li et al., 2011). In addition to 
AChBPs, the Torpedo marmorata (marbled electric ray) electric 
organ nAChR (Unwin, 2005) has been extensively studied as a 
model for the heteropentameric muscle-type nAChR (Miyazawa 
et al., 2003).
In parallel with structural studies on these nAChR 
homologues, short- and long-chain 3FTxs from snake venom, 
such as α-bungarotoxin from Bungarus multicinctus (many-
banded krait) (Huang et al., 2013), α-cobratoxin from Naja 
kaouthia (monocled cobra) (Bourne et al., 2005), and erabutoxin 
from Laticauda semifasciata (black-banded sea krait) (Servent 
et al., 1997), have been employed as ligands to characterize the 
binding interfaces between toxins and nAChRs. In mutagenesis 
studies using recombinant or purified toxins in combination 
with the neuronal or the Torpedo nAChRs, short-chain 3FTxs 
were shown to interact with high affinity with the muscle-type 
receptor (Antil et al., 1999; Servent et al., 2000), while long-
chain 3FTxs effectively bound to both the muscle and neuronal 
α7-nAChRs (Servent et al., 1997; Antil-Delbeke et al., 2000). 
Nevertheless, these studies employed a limited number of isolated 
snake toxins and thus did not expose these receptors to all of the 
various 3FTx isoforms present in a single venom to investigate 
their interactions. More recently, AChBPs have been utilized 
for profiling venom neurotoxicity using a microfluidic system, 
resulting in the detection of low-affinity binders, such as venom 
phospholipases A2 (PLA2), that interact with AChBP, in addition 
to 3FTxs (Slagboom et al., 2018). Other studies have reported the 
ability of a N. kaouthia PLA2 to block acetylcholine currents in 
Lymnaea stagnalis neurons or to compete with α-bungarotoxin 
for binding to Torpedo or α7-type receptors (Vulfius et al., 
2014). The purified Torpedo nAChR has also been employed in 
in vitro assays to assess antivenom efficacy against the venoms 
Abbreviations: nAChR, nicotinic acetylcholine receptor; AChBPs, acetylcholine-
binding proteins; 3FTx, three-finger toxin; Ls-AChBP, Lymnaea stagnalis AChBP; 
PLA2, phospholipase A2; vNGF, venom nerve growth factor
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of N. kaouthia (Thai monocled cobra), N. naja (Indian cobra), 
and B. candidus (Malayan krait) (Ratanabanangkoon et al., 2017, 
Ratanabanangkoon et al., 2018).
In this study, we aimed to assess the nAChR-binding 
specificities of toxins found in a variety of elapid snake venoms 
sourced from distinct geographic regions by employing two 
recombinant neuronal nAChR mimics: the Ls-AChBP and the 
humanized α7-AChBP. Using a ligand-fishing approach, we 
characterized the AChBP-bound and AChBP-unbound fractions 
from seven elapid venoms by SDS-PAGE and mass spectrometry. 
We find that AChBPs effectively capture long-chain 3FTxs from 
a variety of snake venoms but have little interaction with short-
chain 3FTxs. We also evaluated whether AChBP mimics could 
be used as therapeutics against envenoming using Naja haje 
(Egyptian cobra) venom in an in vivo murine model of venom 
lethality. Our data suggest that nAChR mimics show potential 
as cross-species adjunct therapeutics against the life-threatening 
pathologies caused by certain postsynaptic venom toxins, 
although future optimization to broaden their specificity against 
other classes of neurotoxins will likely be required to fully exploit 
their therapeutic potential.
MATERIALS AND METHODS
AChBP Expression and Purification
The AChBP from Lymnaea stagnalis (Ls-AChBP) and α7-AChBP 
were expressed and purified as previously described (Spurny 
et  al., 2015) with slight modifications. In brief, a C-terminal 
His-tagged fusion of the protein was expressed in Sf9 insect 
cells (a clonal isolate of Spodoptera frugiperda Sf21 cells) using 
the Bac-to-Bac baculovirus expression system (Invitrogen). 
AChBPs were purified from the expression medium by adding 
Ni Sepharose 6 Fast Flow beads (GE Healthcare). The beads 
were collected on a column, and impurities were washed with 
buffer containing 20 mM Tris–Cl (pH 8.0), 300 mM NaCl, and 
40 mM imidazole. AChBP was eluted with the same buffer 
containing 300 mM imidazole. Fractions containing AChBP 
were pooled, concentrated, and further purified using size-
exclusion chromatography on a Superdex 200 10/300 GL column 
(GE Healthcare) and a running buffer containing 20 mM Tris–
Cl (pH 8.0) and 150 mM NaCl. Fractions corresponding to the 
pentameric protein were pooled, concentrated to 6 mg/ml, snap-
frozen in liquid nitrogen, and stored at −80°C until further use.
Snake Venoms
Venoms were sourced from either wild-caught specimens 
maintained in or historical venom samples stored in the 
Herpetarium of the Liverpool School of Tropical Medicine. 
The venoms selected were from diverse geographical localities 
and were from: Naja haje (Egyptian cobra, Uganda), Naja naja 
(Indian cobra, captive bred origin), Naja kaouthia (monocled 
cobra, captive bred, likely of Thai ancestry), Bungarus caeruleus 
(common krait, historical venom of Indian origin), Dendroaspis 
viridis (West African green mamba, Togo), Micrurus fulvius 
(eastern coral snake, historical venom of USA origin), and 
Oxyuranus scutellatus (coastal taipan, Australia). Crude venoms 
were lyophilized and stored at 4°C to ensure long-term stability. 
Before use, venoms were resuspended to 10 mg/ml in PBS (pH 
7.4) and then further diluted to 1 mg/ml stock solutions (with 
PBS) for the described experiments.
Transcriptomics and Molecular Data
We constructed venom gland transcriptomes from single 
individuals for N. haje (n = 1, Uganda, wild-caught), N. naja (n = 1, 
captive bred of Indian origin), and N. kaouthia (n = 1, captive 
bred of Thai origin), from glands dissected 3 days post-venom 
extraction, using methods previously described by our group 
(Pla et al., 2017; Ainsworth et al., 2018a; Whiteley et al., 2018). 
The venom of the animals used for transcriptomics was either 
used for direct comparison for the N. kaouthia specimen or 
contributed to the venom pools used in this study for N. haje 
(the venom of six snakes from Uganda) or N. naja (historical 
venom pool of an unknown number of donor snakes of Indian 
ancestry). Briefly, the snakes were euthanized using an overdose 
of pentabarbitone, and the venom glands were excised and 
immediately flash frozen in liquid nitrogen. The venom gland 
tissue was homogenized under liquid nitrogen using a pestle 
and mortar and a TissueRuptor (QIAGEN), and total RNA was 
extracted using the TRIzol Plus RNA Purification System (Thermo 
Fisher) protocol. Resulting RNA samples were DNAse treated 
(On-Column PureLink DNase; Life Technologies) and total 
RNA eluted in 30 µl nuclease-free water (Qiagen). The RNA then 
underwent two rounds of poly(A) selection using the Dynabeads 
mRNA DIRECT purification kit (Life Technologies) and was 
eluted in nuclease-free water before the quality and quantity 
of isolated RNA was assessed using a Bioanalyzer (Agilent). 
Subsequently, the sequencing library was prepared using 50 
ng of enriched RNA using the Script-Seq v2 RNA-Seq Library 
Preparation Kit (epicenter), following 12 cycles of amplification. 
The sequencing library was then purified using AMPure XP 
beads (Agencourt), quantified using the Qubit dsDNA HS Assay 
kit (Life Technologies), and the size distribution assessed using 
a Bioanalyzer (Agilent). Sequencing libraries were multiplexed 
with others not reported in this study, and sequencing was 
performed on an Illumina MiSeq platform using 250 bp paired-
end read technology (Centre for Genomics Research, University 
of Liverpool). Each of the three samples represented one-sixth of 
a sequencing lane. The ensuing read data were quality processed 
as previously described (Ainsworth et al., 2018a), resulting in the 
removal of adapter sequences (Cutadapt; https://code.google.
com/p/cutadapt/) and low-quality bases (Sickle; https://github.
com/najoshi/sickle). Paired-end read data were then assembled 
into contigs using VTBuilder (Archer et al., 2014) with the 
following parameters: minimum transcript length, 150 bp; 
minimum read length, 150 bp; and minimum isoform similarity, 
96%. Assembled contigs were then annotated using BLAST2GO 
Pro v3 (Conesa et al., 2005) using the blastx-fast algorithm with 
a significance threshold of 1e−5 against NCBI’s nonredundant 
(NR) protein database (41 volumes, Nov 2015). Following 
annotation, contigs were assigned to one of the following three 
categories: toxins (contigs with blast annotations to sequences 
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previously described as pathogenic toxins), nontoxins (contigs 
matching other sequences, such as housekeeping genes), and 
unidentified (those with no matches assigned or hits <1e−5). 
Toxin contigs were then manually analyzed using sequence 
alignments generated by the MUSCLE algorithm (Edgar, 2004) 
embedded within MEGA v7 (Kumar et al., 2016) for quality 
control purposes, including the merging of contigs that exhibited 
100% identity to one another in overlapping regions  >50 bp 
long (indicative of underclustering during assembly), the 
identification of open reading frames, and the removal of contigs 
containing stop codons within the coding region. Finally, the 
toxin encoding contigs were translated using MEGA v7 and 
ExPASy Translate (https://web.expasy.org/translate/) to generate 
species-specific toxin databases for proteomic analyses (see 
below). Thus, for the cobras and D. viridis, we used translations 
of venom gland transcriptomic data generated in this study or 
previously published by our group (Ainsworth et al., 2018a). 
For N. kaouthia, we only used translations of the venom gland 
transcriptome generated in this study (and not other previously 
published studies), as venom from this same specimen was used 
in our AChBP pulldowns. For M. fulvius and O. s. scutellatus we 
used existing sequence resources available on Uniprot (accessed 
July 2018) (Herrera et al., 2012; Vergara et al., 2014). Lastly, 
for B. caeruleus, we extracted all proteomic data present in 
Uniprot (Oh et al., 2017) and supplemented it with translations 
of toxins from a venom gland transcriptome of its congener, 
B. multicintus (Jiang et al., 2011), to increase coverage and 
breadth of 3FTxs. A supplementary fasta file containing all of 
the translated toxins encoding sequences, and all of the protein 
sequences sourced from Uniprot, that together were used for our 
proteomic identifications, is available as Supplementary Data 
Sheet 2. Raw sequencing reads and resulting de novo assemblies 
generated for the N. haje, N. naja, and N. kaouthia venom gland 
transcriptomes have been deposited in the NCBI Sequence Read 
Archive (SRA) and Transcriptome Shotgun Assembly (TSA) 
databases, respectively, and are linked to the BioProject identifier 
PRJNA506018.
Capture and Purification of Venom Toxins 
Using Magnetic Beads
Ligand-fishing using AChBP was adapted from a previously 
published method (Pochet et al., 2011). Briefly, 20 µg of venom 
and 20 µg of recombinant α7-AChBP were brought up in binding 
buffer (1 mM KH2PO4, 3 mM Na2HPO4, 0.16 mM NaCl, 20 
mM Tris–Cl, pH 7.5) to a final volume of 200 µl and incubated 
for 2 h at room temperature with gentle agitation. Another 
sample containing 10 µg of venom and 4.8 µg of α7-AChBP 
was also incubated alongside these samples but did not undergo 
separation using magnetic beads. Dynabeads (His-Tag isolation 
and Pulldown, Thermo Fisher Scientific, cat. No.: 10103D) were 
washed three times in binding buffer and resuspended at a final 
concentration of 20 mg/ml. Thirty microliters of Dynabeads 
were then added to each sample and incubated for another 15 
min with gentle agitation. The beads were next separated using 
a magnetic stand, and the flow-through was recovered as the 
“unbound” fraction. The beads were washed four times with 200 
µl wash buffer (50 mM sodium phosphate buffer pH 8.0, 300 mM 
NaCl, 0.01% Tween-20), allowing 2 min for magnetic separation. 
The bound AChBP and toxin-AChBP complexes were eluted in 
12 µl of His elution buffer (300 mM imidazole, 50 mM sodium 
phosphate buffer pH 8.0, 300 mM NaCl, 0.01% Tween-20) and 
resuspended 1:1 in 2× SDS-PAGE gel loading dye under reducing 
or nonreducing conditions and loaded onto 15% SDS-PAGE gels. 
The unbound and control sample were concentrated up to ~15 
µl using a speedvac, after which they were resuspended 1:1 in 2× 
SDS-PAGE loading buffer. For the Ls-AChBP, the conditions were 
the same, with the exception that 50 µl of 40 mg/ml Dynabeads 
was used to capture the AChBP and the elution volume was 30 µl.
One-Dimensional SDS-PAGE Gel 
Electrophoresis
We used SDS-PAGE gel electrophoresis to evaluate the bound 
and unbound fractions in each of our profiled venoms following 
the ligand-fishing assay. For each venom, we ran SDS-PAGE 
gels containing the following five lanes: 10 μg of venom, 2.5 
μg of AChBP, a mixture containing 10 μg of AChBP + 4.8 μg 
venom, and the entire bound and unbound fractions. Samples 
were diluted 1:1 with a reducing or nonreducing loading buffer. 
Samples were then loaded onto 15% hand-cast SDS-PAGE gels 
alongside a protein marker (Broad Range Molecular Marker, 
Promega) and run at 120 V for 90–100 min using a Mini-
PROTEAN Tetra System (Bio-Rad). The resulting gels were 
stained with Coomassie brilliant blue for 2 h and then destained 
(4.5:1:4.5 methanol/acetic acid/H2O) for visualization.
Two-Dimensional SDS-PAGE Gel 
Electrophoresis
We used our previously described method (Ainsworth et al., 
2018b; Calvete et al., 2018) to perform two-dimensional (2D) 
SDS-PAGE gel electrophoresis experiments using N. haje venom. 
Ligand fishing was scaled up appropriately using 100 μg of 
α7-AChBP and 100 μg of N. haje venom. The AChBP and venom 
were incubated for 30 min at room temperature, after which 
the purification was carried out as described above. The bound 
and unbound fractions were prepared for 2D gel electrophoresis 
using the ReadyPrep™ 2-D Cleanup Kit for isoelectric focusing 
(IEF) (Bio-Rad) as per the manufacturer’s instructions. 
Cleaned-up venom samples were then applied to 7 cm, pH 3–10, 
nonlinear IPG strips (Bio-Rad) using the ReadyPrep™ 2-D starter 
kit (Bio-Rad), as per manufacturer’s instructions and rehydrated 
overnight at room temperature. After rehydration, IEF was 
performed using a PROTEAN® IEF Cell (Bio-Rad) with the 
manufacturer’s standard electrophoresis protocol for 7 cm IPG 
strips (default cell temperature = 20°C; maximum current 50 µA/
strip; voltage = 250 V with linear ramp for 20 min; 4,000 V with 
linear ramp for 2 h; 4,000 V with rapid ramp for 10,000 V-h). 
After IEF, IPG strips were equilibrated (as per the ReadyPrep™ 
2-D starter kit) and loaded onto Mini-PROTEAN TGX AnyKd 
precast gels (Bio-Rad) and run at 200 V for 35 min. Gels were 
then rinsed in water and stained with G-250 Coomassie blue 
stain (Bio-Rad) for 2 h to visualize the proteins.
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In-Gel Tryptic Digestion of Proteins
All visible protein bands under ~20 kDa were excised from the 
1D nonreducing and 2D gels for both the bound and unbound 
fractions (Supplementary Figure 1) and prepared for mass 
spectrometry. Gel slices were cut into small pieces and washed 
twice in washing buffer 1 [100 mM ammonium bicarbonate, 
50% acetonitrile (ACN)], followed by three ACN washes and 
centrifuged at top speed in a microfuge to pellet the gel particles. 
The samples were then incubated in 40 μl reduction buffer (25 
mM ammonium bicarbonate, 0.5% β-mercaptoethanol) for 40 
min at 56°C to reduce the disulfide bridges and alkylated with 
55 mM iodoacetamide for 20 min in the dark. Next, the gel 
slices were alternatively washed with washing buffer and ACN 
until they turned white (no residual dye left), after which they 
were dried in a vacuum centrifuge. Samples were trypsinized 
overnight at 37°C with 0.6 µg of trypsin (Sigma, cat. no.: T6567) 
per sample, after which 1 μl of 5% formic acid (FA) was added to 
the tubes to quench the digestion. The samples were sequentially 
extracted in 0.1% FA, 0.1% FA and 50% ACN, and finally 100% 
ACN, and moved to autosampler vials with glass inserts.
NanoLC-MS/MS of Tryptic Digests and 
Data Analysis
The NanoLC separation of the tryptic digests was performed 
using an UltiMate 3000 RSLCnano system (Thermo Fisher 
Scientific). The autosampler was run in full-loop injection 
mode. The autosampler was set to a 1-µl injection volume, and 
after injection, the samples were separated on an analytical 
capillary column (150 mm × 75 µm) with Aqua C18 particles, 
packed in-house (3 µm particle size and 200 Å pore diameter; 
Phenomenex). The mobile phases comprised eluent A (98% H2O, 
2% ACN, 0.1% FA) and eluent B (98% ACN, 2% H2O, 0.1% FA). 
The gradient program used for the separation was as follows: 
2 min isocratic separation at 5% B, linear increase to 80% B in 
15 min, 3 min isocratic separation at 80% B, down to 5% B in 
0.5 min, and equilibration for 9 min. The column was kept at 
30°C in the column oven. Detection was performed by a variable 
wavelength detector set at 254 nm followed by a Bruker Maxis 
q-TOF mass spectrometer (Bruker). The mass spectrometer was 
operated in positive-ion mode and had an electrospray ionization 
(ESI) source. The ESI source parameters for the MS instrument 
consisted of the following: source temperature, 200°C; capillary 
voltage, 4.5 kV; and gas flow, 10 l/min. Spectra were obtained at 
1 spectrum/s in the 50–3,000 m/z range. MS/MS spectra were 
obtained in data-dependent mode using 35-eV collision energy 
in the CID collision cell. Bruker Compass software was used for 
instrument control and data analysis.
Mascot (Matrix Science) searches against our custom 
databases (see above, Supplementary Data Sheet 2) were used 
for protein identification of the analyzed tryptic digests. The 
following search parameters were used: ESI-QUAD-TOF as the 
instrument type, semiTrypsin as the digestion enzyme allowing 
for one missed cleavage, carbamidomethyl on cysteine as a fixed 
modification, amidation (Protein C-term) and oxidation on 
methionine as variable modifications, ± 0.05 Da fragment mass 
tolerance, and ±0.2 Da peptide mass tolerance.
In addition to providing details on the resulting toxin coverage 
derived from the recovered peptides (see Supplementary 
Tables 1 and 2), we transformed the resulting data to provide an 
overview of peptide matching by extracting the unique peptides 
identified in our Mascot searches and then calculating a score 
for each identified toxin as the number of unique peptides per 
protein divided by the number of amino acids in that protein.
Molecular Analysis of 3FTxs
The bound and unbound 3FTxs from the various snake species 
were aligned in MEGA v7 using MUSCLE and then manually 
curated and validated. The resulting alignments were then 
exported and annotated in Jalview (http://www.jalview.org) for 
figure production.
Assessing the Efficacy of AChBP in vivo
Animal experiments were conducted using protocols approved by 
the Animal Welfare and Ethical Review Boards of the Liverpool 
School of Tropical Medicine and the University of Liverpool, and 
they were performed in specific pathogen-free conditions under 
licensed approval of the UK Home Office and in accordance with 
the Animal (Scientific Procedures) Act 1986 and institutional 
guidance on animal care. Experimental design was based upon 
refined WHO-recommended protocols (Harrison et al., 2017), 
and the investigators conducting the experiment were blinded to 
the treatment each group of mice would receive.
The median lethal dose (venom lethal dose 50 [LD50]) of N. 
haje venom (0.43 µg/g body weight) used in this experiment 
was previously determined (Harrison et al., 2017). Similarly, 
the median effective dose (effective dose 50 [ED50]) of SAIMR 
polyvalent against 5 × LD50 N. haje venom was previously 
determined to be 71 µl (Harrison et al., 2017). Owing to 
limited amounts of AChBP, we used 2.5 × LD50 doses of N. 
haje venom (20.4 µg) in a modified version of the antivenom 
ED50 neutralization experiments (Ainsworth et al., 2018b). 
Groups of five male 18–22 g CD-1 mice (Charles River, UK) 
received experimental doses, which comprised either a) venom 
only (2.5  × LD50, 20.4 µg); b) venom and SAIMR polyvalent 
antivenom [either the “suboptimal” dose of 0.25 × ED50 (17.75 
µl) or the “protective” dose of 0.75 × ED50 (53.25 µl)], both 
previously determined against 5 × LD50 venom doses; c) venom 
and “suboptimal” dose of antivenom and α7-AChBP (102 µg); 
d) “suboptimal” dose of antivenom only; or e) α7-AChBP (102 
µg) only. All experimental doses were prepared to a volume of 
200 µl in PBS and incubated at 37°C for 30 min before their 
intravenous injection via the tail vein. The mice were monitored 
for 6 h and euthanized upon observation of humane endpoints 
(seizure, pulmonary distress, paralysis). Deaths, time of death, 
and survivors were recorded, where “deaths/time of death” 
actually represents the implementation of euthanasia based on 
the defined humane endpoints.
For statistical analysis, we performed a one-way ANOVA 
with Tukey’s post hoc test on the means of the five independent 
measurements in GraphPad Prism7, using default parameters. It 
is worth noting that this model utilizes the intravenous delivery 
of venom in order to cause venom-induced lethality within an 
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acceptable experimental time frame and to reduce unnecessary 
suffering in experimental animals. However, the intravenous 
delivery of venom does not accurately reflect a human snakebite, 
and thus, the therapeutic doses used in this study cannot be 
easily extrapolated to anticipate the therapeutic doses that might 
be required clinically.
RESULTS
Ligand Fishing with Ls- and α7-AChBP 
Captures Low Molecular Weight Toxins
To characterize the binding specificity of toxins from various 
neurotoxic elapid venoms to nAChRs, we used a ligand-fishing 
approach adapted from a previously published method (Pochet 
et  al., 2011). Elapid venoms (N. haje, N. naja, N. kaouthia, D. 
viridis, B. caeruleus, M. fulvius, and O. s. scutellatus) were incubated 
with recombinant His-tagged nAChR mimics (α7-AChBP or 
Ls-AChBP), after which the toxin-bound fraction was purified 
using magnetic beads. The venom, AChBP, and bead amounts, as 
well as the incubation times, were optimized with N. haje venom 
(Supplementary Figure 2), a representative venom rich in 3FTxs 
(Malih et al., 2014). The bound and unbound fractions were then 
separated on SDS-PAGE gels under reducing and nonreducing 
conditions (Figures 1A, B and Supplementary Figure  3). The 
monomeric α7- or Ls-AChBPs were observed at ~25 kDa, 
and some AChBP dimers and pentamers were noted under 
nonreducing conditions, which dissociated in the presence of a 
FIGURE 1 | Toxins captured using the AChBP ligand-fishing assay. Nonreducing 1D and 2D SDS-PAGE gels showing the bound and unbound fractions from N. 
haje (NH), N. naja (NN), N. kaouthia (NK), D. viridis (DV), B. caeruleus (BC), M. fulvius (MF), and O. s. scutellatus (OS) venoms. The gels display the bound and 
unbound (FT) fractions from purifications using the α7-AChBP (A) and Lymnaea stagnalis AChBP (Ls-AChBP) (B) binding proteins. Venom alone and a mixture of 
both the venom and binding protein are also presented as controls. (C) 2D SDS-PAGE gels for the bound (left) and unbound fractions (right) collected from N. haje 
venom incubated with α7-AChBP.
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reducing agent. Moreover, while proteins in the 3FTx molecular 
weight range (~7–12 kDa) were recovered in both the bound 
and unbound fractions, the patterns of these bands differed, 
suggesting that specific toxins may be differentially captured by 
these AChBPs. In addition, these patterns were not markedly 
different between the humanized α7-AChBP and the Lymnaea 
Ls-AChBP, suggesting that these two types of nAChR mimics 
may be capturing similar toxins. To better resolve the captured 
fraction from the flow-through (i.e., to test for the potential of 
multiple captured toxins being present in single protein bands), 
we chose the humanized α7-AChBP and N. haje venom and 
performed 2D gel electrophoresis. However, this approach did 
not additionally distinguish between the protein bands in the 
3FTx molecular weight range (~7–12 kDa), suggesting that our 
1D-gel approach was appropriate for identifying toxins that bind 
to AChBPs (Figure 1C).
Notably, some AChBP leakage into the unbound fraction was 
observed with N. kaouthia venom (Figure 1). This may be due 
to components in the venom denaturing the binding protein or 
masking the His-tag, thus hindering the binding of the AChBP 
to the beads, as this phenomenon was apparent when using 
both α7-AChBP and Ls-AChBP for ligand fishing. To a lesser 
extent, this was also observed with venom from D. viridis (Ls 
fractionation). Importantly though, the leakage of these AChBPs 
into the supernatant does not appear to markedly affect the 
patterns of the captured toxins. Overall, our results suggest that 
the α7- and Ls-AChBPs differentially bind proteins in the 3FTx 
molecular weight range.
Long-Chain 3FTxs Bind With High Affinity 
to AChBPs
To elucidate the differences between the bound and unbound 
toxin fractions, the relevant protein bands were isolated from 
SDS-PAGE gels and subjected to tryptic digestion and mass 
spectrometry. To identify the resulting peptides, we initially 
performed a Mascot search using the SwissProt database. 
However, as snake venom proteins are not extensively 
represented in this database, the quality of the recovered matches 
was suboptimal, with very few matches obtained for our venoms 
of interest, and typically assigned to toxins identified from 
related snake species. To resolve this identification bottleneck, 
we utilized translations of transcriptomic data sourced from the 
venom glands of our species of interest as custom databases for 
MS/MS Mascot searches (see Supplementary Data Sheet 2). To 
this end, we generated and analyzed venom gland transcriptomes 
and their translations for N. haje, N. naja, and N. kaouthia, whose 
venoms were either utilized directly in this study (N. kaouthia) 
or contributed to the venom pool employed in the AChBP 
experiments (N. haje and N. naja). Existing, transcriptomic [D. 
viridis (Ainsworth et al., 2018a)] or proteomic resources [M. 
fulvius (Vergara et al., 2014), B. caeruleus (Oh et al., 2017), and O. 
s. scutellatus (Herrera et al., 2012)] were used for the remaining 
species under investigation.
In line with previous findings (Servent et al., 1997; Antil-
Delbeke et al., 2000), our MS/MS identifications revealed that 
long-chain 3FTxs (long-chain α-neurotoxins) were consistently 
captured by both AChBPs when incubated with the three cobra 
venoms (Naja spp). and that of the common krait (B. caeruleus) 
(Figure 2, Supplementary Tables 1–3). Moreover, the protein 
IDs identified with both these AChBPs were largely consistent. 
In the cobra venoms, the detected peptides amounted to ~60% 
sequence coverage for long-chain 3FTxs, while α-δ-bungarotoxin 
4 was the top binder in B. caeruleus venom. In contrast, the 
highly similar short-chain 3FTxs (short-chain α-neurotoxins) 
were almost exclusively observed in the unbound fraction, or 
a similar number of peptides were identified in both the bound 
and unbound fractions (Supplementary Table 3), suggesting a 
rapid exchange between the on- and off-bead fractions. Thus, if 
these short-chain 3FTx isoforms are being captured, they are not 
tightly associated with AChBPs, suggesting either weak binding to 
the receptor or background noise. Bearing in mind the presence 
of AChBP in the flow-through when incubating with N. kaouthia 
venom, we observed a relatively equal distribution of long-chain 
3FTxs between the bound and unbound fractions (e.g., 17 vs. 
19 peptides for Ls-AChBP and 10 vs. 8 peptides for α7-AChBP 
recovered for long-chain 3FTx T1411, Supplementary Table 3), 
likely due to the association of some long-chain 3FTxs with an 
AChBP that cannot interact with the magnetic beads; however, 
this data nevertheless suggest that long-chain 3FTxs are still 
being captured in this venom.
In contrast to our results with venom from Naja spp. and B. 
caeruleus, no long-chain 3FTxs were recovered from the bound 
fractions following the incubation of the two AChBPs with D. 
viridis venom. We did detect one short-chain 3FTx bound to the 
AChBPs, but this toxin was also recovered in the unbound fraction 
(Figure 2). However, a previous analysis of the D. viridis venom 
gland transcriptome (Ainsworth et al., 2018a) demonstrated that 
while this species contains three long-chain 3FTx transcripts, 
all have very low expression (<0.1% of all venom toxins in the 
transcriptome). It is therefore unsurprising that these toxins were 
not detected via our approach. Furthermore, the short-chain 3FTx 
recovered from the bound fraction is the most highly expressed 
toxin in the D. viridis transcriptome (19.4% of all venom toxins) 
and represents 40.1% of the D. viridis proteome (Ainsworth et al., 
2018a). The abundance of this short-chain 3FTx likely explains its 
transitory binding to AChBPs at high concentrations.
We did not observe any 3FTxs in the bound fractions from 
M. fulvius venom, and only one peptide from a short-chain 3FTx 
was recovered in the unbound fraction. Several PLA2 isoforms in 
this venom bound weakly to Ls-AChBP, but with one exception; 
we only recovered a few peptides for these toxins, while several 
PLA2 isoforms were observed in the flow-through. This low level 
of binding is potentially due to the high abundance of these toxins 
in the venom, as the M. fulvius venom gland transcriptome is 
dominated by PLA2s (~65% of toxin expression), with only 21% 
of transcripts encoding 3FTxs (Margres et al., 2013). While the 
M. fulvius venom proteome was previously shown to contain 
6–7 kDa nAChR-binding toxins, which made up 24.9% of the 
venom toxins, these toxins typically exhibited only weak and 
reversible binding to the muscle-type nAChR in a cell-based 
assay (Vergara et al., 2014). In the current study, we employed 
two types of α7-neuronal receptor mimics that appear to only be 
effectively binding long-chain, but not short-chain, 3FTxs across 
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the species tested. Analysis of a sequence alignment of M. fulvius 
3FTxs sourced from the venom gland transcriptome (Margres 
et al., 2013) revealed an absence of canonical long-chain 
3FTxs (Supplementary Figure 4) and thus may explain these 
observations. Given that we only detect PLA2s from M. fulvius 
venom being weakly captured by the AChBPs, we conclude that 
these may be binding to Ls-AChBP at background levels, in a 
similar manner to previously reported interactions between viper 
or elapid PLA2s and this AChBP, which occur in the micromolar 
range (Vulfius et al., 2014; Slagboom et al., 2018).
Similarly, no 3FTx bands were recovered in the bound fraction 
of O. s. scutellatus venom, which is unsurprising as the O. s. 
scutellatus venom proteome consists of only 1.5% 3FTxs, while 
PLA2s represent 79.4% of all venom toxins (Herrera et al., 2012). 
In addition, the high neurotoxicity of this venom is driven by 
presynaptic neurotoxins (Kornhauser et al., 2010), among which 
taipoxin, a PLA2 heterotrimer, is the most toxic component 
isolated from snake venom to date. Upon visual inspection of all 
aligned 3FTxs in our dataset (Supplementary Figure 5), we did 
not identify any canonical long-chain 3FTxs. While long-chain 
3FTxs (e.g., LNTX-1) have been proteomically annotated from O. 
s. scutellatus venom (Herrera et al., 2012), our analysis shows that 
this isoform does not contain the additional cysteines required to 
make the extra fifth disulfide bond characteristic of long-chain 
3FTxs and, therefore, may have been misannotated based on its 
protein length. As with M. fulvius, our data imply that long-chain 
3FTxs are not being captured from O. s. scutellatus because they 
may not be present in the venom.
Interestingly, we also identified venom nerve growth factor 
(vNGF) as an AChBP binder in several of the venoms surveyed. 
The toxic role of vNGF remains unclear, and it represents a minor 
venom component in almost all snake venoms from which it 
has been recovered (Tasoulis and Isbister, 2017). vNGF was 
effectively captured by both α7- and Ls-AChBP from the venoms 
of N. haje, N. kaouthia, and M. fulvius, while vNGF from N. naja 
venom only appeared to interact with Ls-AChBP. These results 
hint at the potential of vNGF to interact with nAChRs, although 
this requires future experimental validation.
FIGURE 2 | Identification of the toxins captured by α7- and Ls-AChBP. The mass spectrometry data were expressed as the number of unique peptides recovered 
per protein divided by the protein length (in amino acids) for all proteins in each of the bound and unbound fractions. Scores (number of peptides per protein length 
in aa) are displayed for the different classes of toxins captured from N. haje, N. naja, N. kaouthia, D. viridis, B. caeruleus, M. fulvius, and O. s. scutellatus venoms 
or recovered in the unbound fraction. Classes of toxins bound by α7-AChBP (A) or Ls-AChBP (B) are categorized into long-chain three-finger toxins (3FTxs), other 
3FTxs, PLA2s, and NGF. Toxins recovered in the unbound fraction are presented in (C) (α7-AChBP) and (D) (Ls-AChBP). Please note that the axes have different 
lengths driven by the number of unique sequences recovered in each fraction.
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Bound 3FTxs Harbor Canonical Long-Chain 
3FTx Features
Our results suggest that AChBPs effectively capture long-chain 
3FTxs and only weakly interact with other toxin classes, such as 
short-chain 3FTxs and PLA2s. To uncover the relevant features 
underlying the interaction of long-chain 3FTxs with AChBPs, we 
generated a sequence alignment of the 3FTxs recovered in the 
bound and unbound fractions of our ligand-fishing experiment, 
using the transcriptomic data (Figure 3). All bound toxins, 
with the exception of the D. viridis short-chain 3FTx described 
earlier, were confirmed as canonical long-chain 3FTxs, as they 
displayed high conservation throughout the second 3FTx loop 
and contained the two additional cysteine residues involved in 
the formation of the fifth disulfide bond (Figure 3). In contrast, 
all 3FTxs recovered in the unbound fraction were either short-
chain 3FTxs, weak neurotoxins, or cardiotoxins.
AChBPs as Therapeutics in a Murine 
Model of Envenoming
Our transcriptomic analysis (Figure 4) predicts N. haje venom 
to be highly enriched in long-chain 3FTxs, as the expression 
of these toxins constitutes ~41% of that of all toxin-encoding 
genes expressed in the venom gland of this species. Since 
AChBPs effectively capture long-chain 3FTxs, we used N. haje 
venom as our model to test whether AChBPs could be used as 
a novel therapeutic approach for treating snake envenoming. 
To this end, we employed the gold-standard preclinical assay 
FIGURE 3 | AChBPs capture available canonical long-chain 3FTxs. (A) Sequence alignment displaying 3FTxs captured (bound) and not captured (unbound) by 
AChBPs in the three Naja venoms. Cysteines are highlighted in red. The canonical disulfide bridges present in all 3FTxs are indicated by the black lines linking 
cysteines, while the gray lines highlight an additional disulfide bridge in loop I for two of the unbound toxins. The red lines indicate the additional cysteine residues 
that characterize long-chain 3FTxs as being distinct from other types of 3FTx. The three 3FTx loops are displayed above the alignment. (B) Comparisons of the 
transcriptomic expression of Naja toxins that were detected (both AChBP bound and unbound) or were not detected by mass spectrometry. Undetected toxins 
consistently had lower transcriptomic expression compared to those detected (whether in the bound or unbound fractions).
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recommended by the World Health Organization (WHO, 2018) 
for assessing the efficacy of snakebite treatments (antivenoms) 
in vivo. We first challenged groups of mice (n = 5) with 2.5 × 
LD50s of N. haje venom via the intravenous route and compared 
survival times with the same dose of venom preincubated with 
102 µg of α7-AChBP (venom/AChBP = 1:5 ratio). We also 
administered the same dose of AChBP in the absence of venom, 
as a control. The absence of detectable adverse effects in the latter 
demonstrated that α7-AChBP is not acutely toxic to mice at this 
dose. However, we observed no difference in the mean survival 
times of the experimental animals that received venom alone and 
those that received venom preincubated with AChBP (6 vs. 6.2 
min, respectively) (Figure 5). Given that AChBPs only captured 
long-chain 3FTxs in our ligand-fishing assays, these data suggest 
that either other toxic components present in the venom (e.g., 
short-chain 3FTxs, etc.) are also capable of causing lethality or 
that binding by AChBP does not result in the neutralization of 
long-chain 3FTxs.
To explore this further, we challenged mice with venom 
preincubated with an antivenom known to neutralize N. haje 
venom (SAIMR polyvalent antivenom) (Harrison et al., 2017). 
We incubated the same dose of venom with a “suboptimal” dose 
of antivenom (17.75 µl) unable to confer protection on its own 
and a “protective dose” predicted to prevent lethality (53.25 µl). 
In comparison with the venom-only control, the “protective” dose 
of antivenom provided complete protection against the lethal 
effects of the venom until the end of the experiment (360 min), 
while the “suboptimal” dose of antivenom prolonged survival by 
51.6 min (Figure 5). The coincubation of N. haje venom with 
the “suboptimal” dose of antivenom and 102 µg of α7-AChBP 
prolonged the survival of the experimental animals for an 
additional 93.4 min, therefore resulting in increased survival for 
145 min when compared to the venom-only control (Figure 5). 
These results demonstrate that the humanized α7-AChBP does 
confer some protection against venom toxins and thus is likely 
neutralizing at least some of the neurotoxicity caused by long-
chain 3FTxs in vivo. It therefore seems likely that other toxic 
components found in the venom of N. haje, which do not interact 
with AChBPs, are responsible for causing the delayed lethality 
observed in this model.
DISCUSSION
Using a ligand-fishing approach to probe nAChR receptor 
mimics with a range of elapid snake venoms, we demonstrate 
herein that AChBPs interact with and capture long-chain 3FTxs 
but fail to bind to highly related 3FTxs, such as short-chain 
FIGURE 4 | The relative expression of toxin families in the Naja haje, N. naja, and N. kaouthia venom gland transcriptomes. Breakdown of the expression levels of 
the toxins (toxinome) present in the N. haje (A), N. kaouthia (B), and N. naja (C) venom gland transcriptomes. (D) Comparisons of the relative expression of long-
chain 3FTxs versus other 3FTxs in the venom gland transcriptomes (toxinome). 3FTx, three-finger toxins; SVMP, snake venom metalloproteinases; NP, natriuretic 
peptides; CTL, C-type lectins; PLA2, phospholipases A2; CRISP, cysteine-rich secretory proteins; Other, other minor expressed venom toxins.
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α-neurotoxins. Long-chain 3FTxs were recovered when using 
both the Ls-AChBP and the humanized α7-AChBP, which exhibit 
24 and 64% identity with the human α7-receptor, respectively (Li 
et al., 2011); interestingly, these molecules specifically bound 
long-chain 3FTxs in a comparable manner. Our findings are 
consistent with prior studies that used purified long-chain 3FTxs 
and demonstrated that they interact with high affinity (Kd in 
the nanomolar range) with neuronal nAChR receptors, whereas 
short-chain 3FTxs only bind weakly (Kd in the micromolar 
range) (Servent et al., 1997).
Previous studies have highlighted the importance of the tip 
of the second 3FTx loop containing the fifth disulfide bridge 
(Servent et al., 1997; Bourne et al., 2005 ), and that of specific 
key residues in this loop (Antil-Delbeke et al., 2000), for the 
interaction between 3FTxs and the interface created between 
any two subunits of the Ls-AChBP. The reduction in this fifth 
disulfide bond in α-cobratoxin followed by dithiopyridylation 
lowered the affinity of this long-chain 3FTx for the α7-nAChR 
to a comparable level to that of short-chain neurotoxins 
(Servent et al., 1997), while a chimeric construct containing the 
fifth disulfide bond of long-chain neurotoxin 1 from Naja oxiana 
inserted into short-chain neurotoxin 2 from the same species was 
sufficient to increase the affinity of this toxin for the α7-nAChR 
to that of long-chain neurotoxins (Lyukmanova et al., 2007). 
Importantly, all 3FTxs that bound to the Ls- or α7-AChBP in 
the present study contained the fifth disulfide bond (Figure 3) 
and conserved Phe29 and Arg33 residues, which have previously 
been shown to interact with the Ls binding pocket (Bourne et 
al., 2005). In contrast, Phe29 was absent, and Arg33 was not 
conserved among the other 3FTxs recovered in the unbound 
fractions, nor did they contain the additional fifth disulfide 
bridge due to the absence of the two cysteine residues harbored 
by long-chain 3FTxs. Mutagenesis studies (Antil et al., 1999; 
Antil-Delbeke et al., 2000; Fruchart-Gaillard et al., 2002) have 
demonstrated that Trp25, Asp27, and Arg33 are also important 
residues for the binding of 3FTxs to both the neuronal and 
muscle-type receptors, while Ala28, Lys35, and the two cysteines 
involved in the fifth disulfide bond (Cys26 and Cys30) selectively 
bind to the α7-nAChR. Trp25, Asp27, and Arg33 were conserved 
across the captured long-chain 3FTxs identified here but not 
among the unbound 3FTxs recovered. In contrast, a neutral 
charge, but not the Ala28 residue itself, was conserved among the 
bound long-chain 3FTxs, while Lys35 was retained by all binders 
with the exception of the N. naja long-chain 3FTx. Moreover, 
α-δ-bungarotoxin 4 was the top AChBP binder from B. caeruleus 
venom, which is consistent with a recent report showing that α-δ-
bungarotoxins interact with the α7-nAChR (Utkin et al., 2019).
Nonconventional 3FTxs can also bind to the neuronal 
α7-nAChR. One such example is candoxin (Nirthanan et al., 
2002), a 66-amino-acid 3FTx neurotoxin from B. candidus 
that binds with high affinity to the α7-nAChR (IC50 = 50 nM) 
via a fifth disulfide bond present in loop I. This is in contrast to 
other weak neurotoxins from N. kaouthia (WTX) (Utkin et al., 
2001) and Naja sputatrix (Wtn-5) (Poh et al., 2002) that bind 
only weakly (micromolar affinity) to this receptor, suggesting 
that other residues beside the fifth disulfide bond located in 
loop I dictate the binding affinity of these toxins to the neuronal 
receptor. Moreover, haditoxin (Roy et al., 2010), a homodimeric 
3FTx from the venom of the king cobra, Ophiophagus hannah, 
was the first reported dimeric toxin to bind to α7-nAChR (IC50 = 
180 nM). Given that haditoxin does not possess a fifth disulfide 
bond or residues important for contacting the α7-nAChR (e.g., 
Ala28, Lys35), it remains unclear how this dimer interacts with 
the neuronal receptor. These observations do suggest that while 
the fifth disulfide bond and specific residues that protrude into 
the binding pocket of the AChBP represent strong binding 
determinants, other contacts could drive the interaction of 
atypical 3FTxs with the α7-nAChR. However, in the present 
study, we did not detect the binding of any nonconventional 
toxins to AChBPs, likely because our ligand-fishing approach 
may only pull out the most abundant of binders. Toxin abundance 
clearly influences binding in our assay (Figure 3), as a highly 
abundant short-chain 3FTx from D. viridis venom was found to 
bind weakly to both the α7- and Ls-AChBPs, while PLA2s, which 
dominate the venom of M. fulvius, were also found to bind to the 
nAChR mimics.
FIGURE 5 | α7-AChBPs prolong survival in vivo when coadministered with 
antivenom. Groups of five mice were intravenously administered with either 
2.5 × LD50s of N. haje venom alone, AChBP alone, venom preincubated with 
AChBP (1:5 venom/AChBP ratio), a protective dose (53.25 µl) of SAIMR 
polyvalent antivenom alone, or venom preincubated with a protective dose 
of SAIMR polyvalent antivenom. A suboptimal dose (17.75 µl) of antivenom, 
which did not extend the survival of the experimental animals for more than 1 
h, was also preincubated with 2.5 × LD50s of venom and AChBP (1:5 venom/
AChBP weight ratio) and delivered intravenously. Experimental animals were 
observed for the duration of the experiment (360 min) and survival times 
monitored. AChBP enhances the effect of antivenom when administered in 
combination with a suboptimal antivenom dose. Data points represent mean 
survival times and error bars represent SDs (n = 5). Ns, not significant,  
**** P < 0.0001, using a one-way ANOVA with Tukey’s test.
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Since nAChR mimics bind long-chain 3FTxs, which are some 
of the most potent neurotoxins found in elapid venoms [with LD50s 
ranging from 0.04 to 0.3 mg/kg (Nirthanan and Gwee, 2004)], we 
were interested in assessing the potential value of AChBPs as novel 
snakebite therapeutics for neurotoxic envenoming. We selected 
N. haje as our model for these studies, as this snake is considered 
to have a highly neurotoxic venom (Malih et al., 2014), and our 
transcriptomic analysis demonstrated that long-chain 3FTxs are 
the major venom components (~41% of all toxins; Figure  4). 
While our in vivo data showed that the intravenous delivery of 
α7-AChBP was unable to protect mice from the lethal effects 
of N. haje venom, we demonstrated that these nAChR mimics 
are likely neutralizing long-chain 3FTxs, as increased survival 
times (P < 0.0001) were observed in envenomed mice treated 
with both α7-AChBP and a “suboptimal” dose of antivenom, 
when compared with the “suboptimal” dose of antivenom alone, 
which only briefly prolonged survival (Figure 5). Thus, the 
ability of α7-nAChR mimics to potentially neutralize a class of 
3FTxs in vivo represents an encouraging prospect to build upon 
in the context of developing future treatments with the goal of 
generically targeting neurotoxicity in envenomed victims.
Given that the binding specificity of this molecule is directed 
predominately towards long-chain 3FTxs, broad-spectrum 
AChBPs capable of capturing a large variety of different 3FTx, 
or a mixture of AChBPs able to neutralize both short- and long-
chain 3FTxs, would likely be needed to effect cure in envenomed 
victims. One advantage of the humanized α7-AChBP used in this 
study is its similarity (~71%) with the human α7-nAChR, which 
may result in reduced immunogenic effects if administered to 
patients. The engineering of broad-spectrum AChBPs would 
ideally also use this humanized molecular backbone while taking 
advantage of the increased affinity (Nirthanan and Gwee, 2004) 
and pharmacological properties of other nAChR mimics, such 
as the Torpedo nAChR. Finally, while we explored the toxin 
capturing potential of AChBPs against a number of geographically 
diverse elapid snakes, such optimized broad-spectrum AChBPs 
would require testing against an increased breadth of venoms, 
including additional species within the elapid genera studied 
here and perhaps also members of the Hydrophiinae (marine 
elapids), whose venoms often contain abundant and highly 
potent α-neurotoxins that are typically not effectively neutralized 
by existing antivenoms (Tan et al., 2015; Tan et al., 2018).
Irrespective of whether a single broad-spectrum nAChR 
mimic or multiple mimics with different specificities would be 
required, such approaches could prove highly advantageous for 
circumventing venom variation—a major limitation with current 
antivenoms, which are typically only effective against a single, or 
a limited number of, snake venom/s. By neutralizing a whole 
class of toxins, a successful receptor mimic would thus represent 
a significant step forward compared to existing polyclonal 
antivenoms, which, given their low economies of scale due to 
restricted geographical usage, result in high costs to impoverished 
snakebite victims (Gutiérrez et al., 2017). Conceptually, this 
approach is analogous to recent studies exploring other non-
antibody therapeutics, such as enzyme inhibitors and metal 
chelators (Ainsworth et al., 2018b; Bulfone et al., 2018), to target 
whole classes of snake venom toxins that cause pathologies 
such as hemorrhage and coagulopathy. Ideally, these AChBP 
mimics would bind rapidly and with high affinity to venom 
toxins, thus precluding their binding to nAChRs in the victim. 
Strong and rapid binding is a highly desirable characteristic 
for new therapeutics, as delays in treatment in resource-poor 
settings inevitably allow 3FTxs to access nAChR receptors before 
treatment administration. Therefore, investigating whether 
AChBPs can effectively displace already bound toxins should be 
a key focus of future research. Nonetheless, our present in vivo 
results show the promise of AChBPs to delay lethality caused 
by neurotoxic snake venom and thus advocate exploring such 
characteristics in future work.
As an alternative to the use of AChBPs as solo therapeutics, 
the coadministration of these molecules alongside traditional 
antivenom therapy may prove to be of greatest value. Prolonged 
survival was observed in our mouse model of envenoming 
when AChBP was administered alongside a suboptimal dose of 
polyvalent antivenom. These findings suggest that AChBPs might 
facilitate reducing clinical doses of antivenom in the future, as only 
10–15% of antivenom immunoglobulins are typically specific to 
venom toxins and only a proportion of those antibodies will be 
specific to highly pathogenic toxins (e.g., 3FTx neurotoxins in 
this case) found in any particular venom (Gutiérrez et al., 2017). 
As many antivenoms require large therapeutic doses to effect 
cure, the further development of a highly specific yet generically 
acting (e.g., irrespective of snake species) inhibitor capable of 
reducing antivenom doses should result in a decreased incidence 
of adverse effects associated with antivenom administration and, 
most importantly, reduce treatment costs.
In an analogous manner, a recent study has demonstrated the 
value of the PLA2 inhibitor varespladib, alone or in combination 
with antivenom, in preventing the onset of neurotoxicity after 
the administration of the neurotoxic O. s. scutellatus venom in 
experimental animals (Lewin et al., 2018). While our model 
venom (N. haje) contains only trace amounts of PLA2s (< 
0.05% of toxins in the venom gland transcriptome), this class 
of enzymes has been found to be more abundant in other cobra 
species (Figure 4) (Tan et al., 2019) and indeed other elapid 
snakes, such as O. s. scutellatus and M. fulvius (Herrera et al., 
2012; Vergara et al., 2014). PLA2s may enable and accelerate 
the spread of the venom after a bite via their cytolytic effects 
(Gutiérrez and Ownby, 2003), thus enhancing the access of other 
venom components to their targets. In the case of elapid snakes, 
PLA2s have also been demonstrated to potentiate the cytotoxic 
effect of specific 3FTxs (Suzuki-Matsubara et al., 2016) and 
may facilitate the rapid action of 3FTxs on their muscular and 
neuronal targets, leading to the onset of paralysis. Therefore, 
combination treatments using AChBPs, enzyme inhibitors such 
as varespladib, and/or antivenom should be extensively explored 
by the scientific community to address current therapeutic 
limitations associated with this lethal neglected tropical disease.
In summary, our study demonstrates a proof of principle that 
AChBP-type proteins can effectively capture entire classes of lethal 
toxins, irrespective of variation in venom composition among 
snake species, and that they may possess therapeutic potential 
when administered in combination with antivenom. Further 
work is required to determine if broad-spectrum AChBPs can be 
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engineered or whether combinations of different AChBPs offer a 
viable strategy to combat neurotoxicity in envenomed snakebite 
victims. Further studies are also required to define the likely 
effective dose of these optimized molecules and whether they are 
likely to be well tolerated by humans. Despite saving thousands of 
lives annually, the numerous limitations associated with existing 
snakebite treatments (e.g., species specificity, limited cross-
reactivity, severe adverse reactions, high cost) strongly advocate 
for research into alternative or adjunct treatments that could 
be used to treat snakebite caused by a wide variety of medically 
important snake species. AChBPs are promising in this regard, and 
their subsequent development and validation may lead to them 
becoming a welcome addition to the snakebite treatment portfolio.
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